SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-22-284669
Filing Date
2022-11-14
Accepted
2022-11-14 16:29:36
Documents
50
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d407409d10q.htm   iXBRL 10-Q 1177612
2 EX-10.1 d407409dex101.htm EX-10.1 186357
3 EX-31.1 d407409dex311.htm EX-31.1 10336
4 EX-31.2 d407409dex312.htm EX-31.2 10344
5 EX-32.1 d407409dex321.htm EX-32.1 5213
  Complete submission text file 0001193125-22-284669.txt   5282768

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cbay-20220930.xsd EX-101.SCH 36838
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cbay-20220930_cal.xml EX-101.CAL 25512
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cbay-20220930_def.xml EX-101.DEF 162015
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20220930_lab.xml EX-101.LAB 278464
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20220930_pre.xml EX-101.PRE 218159
44 EXTRACTED XBRL INSTANCE DOCUMENT d407409d10q_htm.xml XML 933985
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36500 | Film No.: 221386296
SIC: 2834 Pharmaceutical Preparations